177Lu-lilotomab satetraxetan在淋巴瘤细胞系中的综合分析:对精准放射免疫治疗及联合方案的启示
本研究在55株B细胞和T细胞来源的淋巴瘤细胞系中分析177Lu-lilotomab satetraxetan的活性。CD37靶向放射免疫治疗对CD37阳性B细胞淋巴瘤(n=46)比CD37阴性T细胞淋巴瘤(n=9)更有效。在DLBCL细胞系中,BCL2或MYC易位与敏感性无关,但耐药GCB-DLBCL细胞系的BCL2表达高于敏感系,加用BCL2抑制剂venetoclax与放射免疫偶联物联用显示协同作用。
要点
- CD37靶向放射免疫治疗在CD37阳性B细胞淋巴瘤细胞系中比CD37阴性T细胞淋巴瘤细胞系更有效。
- 在DLBCL细胞系中BCL2或MYC易位与敏感性不相关,但耐药GCB-DLBCL细胞系的BCL2表达高于敏感系。
- BCL2抑制剂venetoclax与放射免疫偶联物联用显示协同作用。
核心结论
- 177Lu-lilotomab satetraxetan是治疗CD37阳性恶性肿瘤的有前景化合物,并识别了候选生物标志物和共靶点以检测和克服癌细胞内在耐药机制。
研究设计与样本
- 研究在55株B细胞和T细胞来源的淋巴瘤细胞系中分析177Lu-lilotomab satetraxetan的活性。
主要发现
- CD37靶向放射免疫治疗对CD37阳性B细胞淋巴瘤(n=46)比CD37阴性T细胞淋巴瘤(n=9)更有效。
- 在DLBCL细胞系中,BCL2或MYC易位与敏感性不相关。
- 耐药GCB-DLBCL细胞系的BCL2表达高于敏感GCB-DLBCL细胞系。
- 加用BCL2抑制剂venetoclax与放射免疫偶联物联用显示协同作用。
- 177Lu-lilotomab satetraxetan的活性模式与CD37靶向抗体药物偶联物或R-CHOP不同。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
177Lu-lilotomab satetraxetan (Betalutin) is an anti-CD37 radioimmunoconjugate evaluated as a single administration therapy for the treatment of patients with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma (DLBCL). 177Lu-lilotomab satetraxetan treatment is well tolerated and shows consistent activity in most of the patients evaluated so far. Herein, we investigated the activity of 177Lu-lilotomab satetraxetan in a panel of 55 lymphoma cell lines of B- and T-cell origin. CD37-targeted radioimmunotherapy was more effective in CD37-positive B-cell lymphomas (n = 46) than in CD37-negative T-cell lymphomas (n = 9). Focusing on DLBCL cell lines, mutations such as BCL2 or MYC translocations were not correlated to sensitivity. However, BCL2 expression was higher in resistant than in sensitive GCB-DLBCL cell lines, and the addition of the BCL2 inhibitor venetoclax showed synergism when added to the radioimmunoconjugate. Finally, the pattern of activity of 177Lu-lilotomab satetraxetan differed from what was achieved with a CD37-targeting antibody-drug conjugate or with Rituximab cyclophosphamide hydroxydaunorubicin (doxorubicin) oncovin prednisone (R-CHOP), indicating the potential benefit of the beta-emitter payload. This systematic analysis of the responsiveness of lymphoma cell lines to CD37-targeting radioimmunotherapy consolidated 177Lu-lilotomab satetraxetan as a promising compound for the treatment of CD37-positive malignancies and identified candidate biomarkers and co-targets to detect and overcome cancer cell-intrinsic resistance mechanisms.
引用
- Patzke S, Cascione L, Melhus KB, et al. Comprehensive analysis of 177Lu-lilotomab satetraxetan in lymphoma cell lines: Implications for precision radioimmunotherapy and combination schemes. Br J Haematol. 2025. PMID: 40967736. doi:10.1111/bjh.70143
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。